Janssen seeks FDA meeting to discuss Simponi complete response
This article was originally published in Scrip
Executive Summary
Janssen Biotech intends to request an end-of-review meeting with the US FDA after the regulator issued a complete response letter to the company for its supplemental BLA for an expanded indication for Simponi (golimumab).